-

Trinity Life Sciences Introduces New Field Force Impact Benchmarking Service

Trinity Stakeholder Voice Offers Biopharma Companies Critical Insights into How to Best Serve Healthcare Providers in a New and Changing Reality

WALTHAM, Mass.--(BUSINESS WIRE)--Trinity Life Sciences, a leader in global life sciences solutions, introduces a new field force impact benchmarking service called Trinity Stakeholder Voice. The service offers critical insights for biopharmaceutical companies looking to lead the market in a new and changing reality.

Stakeholder Voice reveals how healthcare providers really feel about their pharmaceutical sales representatives and/or medical science liaisons. The service allows biopharma companies to benchmark how their frontline teams are doing in terms of outreach frequency and quality of interactions compared to competitors in the same indication. The Trinity-sponsored market research is conducted on the top ten brands in a specific indication. Stakeholder Voice is a bi-annual benchmark of sales representative and/or medical science liaison performance allowing companies to see how frontline interactions evolve over time.

Traditional frontline representative visits to healthcare practices have dramatically changed since COVID-19 and pharma companies need to identify new or updated approaches for these one-on-one conversations. Some companies have adjusted faster than others to this new reality and Trinity Stakeholder Voice helps companies identify what is working well and what is not.

“Now more than ever, in an ever-changing pandemic environment, it is critical that biopharmaceutical companies maximize their interactions with healthcare professionals,” said Neal Dunn, Senior Partner and Head of Insights and Analytics, Trinity. “Trinity Stakeholder Voice reveals the types of interactions that healthcare providers feel add value when prescribing a certain brand. This knowledge allows pharma companies to proactively train their frontline representatives to offer the best service.”

Currently Supported Studies*

  • Breast Cancer
  • Colorectal Cancer
  • Non-small Cell Lung Cancer
  • Prostate Cancer
  • Rheumatoid Arthritis and Psoriatic Arthritis
  • Psoriasis and Atopic Dermatitis
  • Crohn’s Disease and Ulcerative Colitis
  • Asthma/Chronic Obstructive Pulmonary Disease
  • Diabetes
  • Multiple Sclerosis
  • Headache
  • Rare – Cardiologists
  • Rare – Neurologists
  • Rare – Hematologists

*Additional indications and ex-US geographies are available on request.

About Trinity Life Sciences
Trinity Life Sciences is a trusted strategic partner, providing evidence-based solutions for the life sciences. With over 20 years of experience, Trinity is committed to solving clients’ most challenging problems through exceptional levels of service, powerful tools, and data-driven insights. Trinity’s range of products and solutions includes industry-leading benchmarking solutions, powered by TGaS Advisors. To learn more about how Trinity is elevating life sciences and driving evidence to action, visit trinitylifesciences.com.

Contacts

Elizabeth Marshall
Trinity Life Sciences
781-577-6376
emarshall@trinitylifesciences.com

Trinity Life Sciences


Release Versions

Contacts

Elizabeth Marshall
Trinity Life Sciences
781-577-6376
emarshall@trinitylifesciences.com

More News From Trinity Life Sciences

Trinity Appoints Scott Evangelista as CEO to Lead Next Chapter

WALTHAM, Mass.--(BUSINESS WIRE)--Trinity, a global leader in technology-enabled commercialization solutions for the life sciences industry, today announced Scott Evangelista has been appointed Chief Executive Officer, succeeding Leslie Orne who is stepping down after three years as CEO and over 24 years with the company. Ms. Orne will transition to the role of Senior Advisor and serve as a member of Trinity’s Board of Directors. Over her distinguished tenure, Ms. Orne helped guide Trinity’s evo...

GSK, Amgen and AstraZeneca Lead the Pack in Trinity’s 2025 Digital Marketing Competency Report

WALTHAM, Mass.--(BUSINESS WIRE)--Trinity, a leader in global life sciences commercialization, today announced the release of its 5th Annual TGaS Digital Marketing Competency Report, a three-part series benchmarking the digital marketing presence of more than 150 biopharma brands. The 2025 edition reveals a significant leap forward in the industry’s digital sophistication, with a 19% increase in Proficient brands and a surge of innovation in patient engagement strategies. The report ranks each b...

Trinity Expands Global Footprint with Acquisition of EVERSANA’s APACME Advisory Services

WALTHAM, Mass.--(BUSINESS WIRE)--Trinity, a leader in global life sciences commercialization solutions and recognized for being a strategic, tech-enabled commercialization company that empowers pharma, biotech, and medtech organizations to advance medical innovations, announced today the acquisition of EVERSANA’s advisory services operation in Asia-Pacific and the Middle East (APACME). The strategic acquisition will transition EVERSANA’s advisory services operation in APACME to Trinity, further...
Back to Newsroom